IL6 and COVID-19: The triggering of coagulopathy in COVID-19 seems to be linked to alveolar damage resulting in an inflammatory storm with activated production of inflammatory cytokines including IL-6, resulting in generation of pro-coagulative factors and damage to endothelium as a prerequisite for thrombosis or arterial to arterial thrombo-embolism (36, 37).